Beta Bionics, Inc. (NASDAQ:BBNX) CFO Sells $26,781.33 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) CFO Stephen Feider sold 1,497 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $17.89, for a total transaction of $26,781.33. Following the completion of the transaction, the chief financial officer now directly owns 45,503 shares of the company's stock, valued at approximately $814,048.67. The trade was a 3.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Beta Bionics Stock Up 8.3%

BBNX traded up $1.49 during trading on Wednesday, reaching $19.45. The stock had a trading volume of 821,154 shares, compared to its average volume of 501,945. The firm's 50-day moving average is $12.75. Beta Bionics, Inc. has a one year low of $8.89 and a one year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.01).

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BBNX shares. Robert W. Baird started coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They set a "neutral" rating and a $20.00 target price for the company. Leerink Partnrs upgraded shares of Beta Bionics to a "strong-buy" rating in a report on Monday, February 24th. Lake Street Capital initiated coverage on shares of Beta Bionics in a report on Monday, February 24th. They issued a "buy" rating and a $30.00 price target for the company. LADENBURG THALM/SH SH assumed coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective for the company. Finally, Bank of America began coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a "buy" rating on the stock. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Beta Bionics currently has an average rating of "Moderate Buy" and a consensus target price of $23.13.

Hedge Funds Weigh In On Beta Bionics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Eventide Asset Management LLC purchased a new position in shares of Beta Bionics in the 1st quarter worth about $60,307,000. Wellington Management Group LLP purchased a new stake in Beta Bionics during the 1st quarter valued at about $47,346,000. Sands Capital Ventures LLC purchased a new stake in Beta Bionics during the 1st quarter valued at about $37,990,000. Omega Fund Management LLC purchased a new stake in Beta Bionics during the 1st quarter valued at about $24,337,000. Finally, Driehaus Capital Management LLC purchased a new stake in Beta Bionics during the 1st quarter valued at about $10,799,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.